Detailed financial statements for Autonomix Medical, Inc. (AMIX): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $4.12, AMIX has negative trailing earnings (P/E not meaningful) and an ROE of -267.73%. Market capitalisation stands at $2M.
Balance sheet quality for AMIX: current ratio of 4.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | $12000 |
| Gross Profit | 0 | 0 | 0 | 0 | -$12000 |
| Research & Development | $4069 | $745000 | $2.2M | $4.7M | $7.1M |
| Selling, General & Admin | $13.6M | $1.2M | $5.2M | $6.9M | $9.9M |
| Operating Expenses | $13.6M | $2.0M | $12.0M | $11.6M | $17.0M |
| Operating Income | -$13.6M | -$2.0M | -$12.0M | -$11.6M | -$17.0M |
| EBITDA | -$13.6M | -$2.0M | -$15.3M | -$11.1M | -$17.0M |
| Interest Expense | $218088 | 0 | $79000 | $176000 | 0 |
| Pre-tax Income | -$13.3M | -$2.0M | -$15.4M | -$11.4M | -$16.7M |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$13.3M | -$2.0M | -$15.4M | -$11.4M | -$16.7M |
| EPS | $-286.98 | $-44.48 | $-343.78 | $-135.65 | $-48.64 |
| EPS (Diluted) | $-286.98 | $-44.48 | $-343.78 | $-135.65 | $-48.64 |
| Shares Outstanding (Diluted) | $44747 | $44747 | $44871 | $84115 | $343655 |
Balance Sheet (10y)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.0M | $865000 | $8.6M | $9.1M | $7.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $2.1M | $865000 | $9.4M | $9.6M | $7.6M |
| Property, Plant & Equipment | 0 | 0 | $16000 | $21000 | $19000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $2.1M | $865000 | $9.4M | $9.8M | $7.6M |
| Accounts Payable | $91622 | $173000 | $492000 | $676000 | $700000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $93242 | $221000 | $777000 | $1.7M | $1.7M |
| Long-term Debt | 0 | 0 | $1.0M | 0 | 0 |
| Total Liabilities | $93242 | $221000 | $1.8M | $1.7M | $1.7M |
| Retained Earnings | -$21.6M | -$23.5M | -$39.0M | -$50.4M | -$67.1M |
| Total Equity | $2.0M | $644000 | $7.6M | $8.1M | $5.9M |
| Total Debt | 0 | 0 | $1.0M | 0 | 0 |
| Net Debt | -$2.0M | -$865000 | -$7.6M | -$9.1M | -$7.0M |
| Working Capital | $2.0M | $644000 | $8.6M | $7.9M | $5.9M |
Cash Flow (10y)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Income | -$13.3M | -$2.0M | -$15.4M | -$11.4M | -$16.7M |
| Depreciation & Amortization | 0 | 0 | $81000 | $183000 | $12000 |
| Stock-based Compensation | 0 | 0 | $618 | $1.6M | $529000 |
| Change in Working Capital | $204414 | $136079 | $79000 | $1.2M | -$107000 |
| Operating Cash Flow | -$387307 | -$1.9M | -$6.6M | -$8.3M | -$12.3M |
| Capital Expenditure | -$3 | 0 | -$19000 | -$14000 | -$10000 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$387310 | -$1.9M | -$6.7M | -$8.3M | -$12.3M |
Growth & Margins (10y)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Income Growth (YoY) | +85.1% | -675.2% | +26.0% | -46.5% | |
| EPS Growth (YoY) | +84.5% | -672.9% | +60.5% | +64.1% | |
| Shares Change (YoY) | +0.0% | +0.3% | +87.5% | +308.6% | |
| FCF Growth (YoY) | -378.8% | -259.5% | -24.1% | -48.6% | |
| Effective Tax Rate | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Per-Share Data (10y)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| FCF Per Share | $-8.66 | $-41.44 | $-148.58 | $-98.34 | $-35.77 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $44747 | $44747 | $44871 | $84115 | $343655 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Profitability
| Return on Equity | -267.73% |
| Return on Invested Capital | -518.15% |
| Return on Assets | -404.67% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 4.85 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -17.84 |
Key Ratios (10y)
| Year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| P/E | -7.42 | -47.87 | -3.67 | -0.27 | -0.17 |
| P/B | 48.63 | 147.96 | 7.41 | 0.38 | 0.48 |
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Related companies: AIM · BBLG · DHAI · FLGC · HSCS · KALA · MOVE
Explore sector: Healthcare · Medical - Devices
More sections of AMIX: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks